Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Sales of Investments
Cash received from selling or redeeming investments.
Evotec SENASDAQ: EVO
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of €919.88K fell 77.6% year over year, behind the +30.9% change in trailing-twelve-month sales of investments. Over 3 fiscal years it compounded at -42.6% a year.
Context
- Sales of investments amounted to 5.1% of revenue in FY2025, up 0.7 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -77.6% toward the trailing-twelve-month pace of +30.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
EUR · from the cash flow
- Latest · FY2025
- 38.87M EUR
- Year-over-year change
- +9.0%
- 4-year CAGR
- +9.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.87M | +9.0% |
| FY2024 | 2024-12-31 | 35.67M | -86.3% |
| FY2023 | 2023-12-31 | 260.36M | +26.9% |
| FY2022 | 2022-12-31 | 205.17M | +652.9% |
| FY2021 | 2021-12-31 | 27.25M | — |
Sales of Investments vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.9% is the 4th highest of 9, against a peer median of +9.8%.
- Sales of investments amounts to 3.5% of revenue for EVO, versus a peer median of 30.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.28B USD | +99.2% | +2.9% | 189.1% | |
| LTM Sep 2026 | $445.96M USD | +31.2% | +56.7% | 492.8% | |
| LTM Sep 2026 | $428.94M USD | +34.1% | +0.7% | 159.3% | |
| LTM Sep 2026 | $328.61M USD | -16.8% | -33.0% | 52.9% | |
| LTM Mar 2026 | $222.13M USD | +8.1% | +4.2% | 30.2% | |
| LTM Feb 2026 | $68.76M USD | +11.5% | — | 5.8% | |
| LTM Mar 2026 | €26.29M EUR | +30.9% | -42.6% | 3.5% | |
| LTM Mar 2026 | $5.95M USD | -45.3% | — | 1.1% | |
| LTM Mar 2026 | $740K USD | — | -33.4% | 0.0% | |
| LTM Sep 2026 | €0 EUR | — | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding EVO) | — | +9.8% | +1.8% | 30.2% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Depreciation & Amortization | 67.61M | 83.2M | 92.98M | 101.62M | 95.55M |
| Deferred Income Tax | 5.07M | 21.7M | 3.32M | 2.1M | 14.11M |
| Stock-Based Compensation | 7.81M | 9.92M | 9.63M | 5.04M | 0 |
| Change in Working Capital | (2.28M) | 105.29M | (9.94M) | (68.21M) | (58.4M) |
| Accounts Receivables | (48.03M) | (53.68M) | 0 | 0 | (27.6M) |
| Inventory | (11.65M) | (4.41M) | 0 | 0 | (9.18M) |
| Accounts Payables | 31.34M | 24.55M | 0 | 0 | (7.02M) |
| Other Working Capital | 26.06M | 138.83M | (9.94M) | (68.21M) | (14.61M) |
| Other Non-Cash Items | (171.47M) | 161.37M | 24.37M | 173.75M | 39.11M |
| Operating Cash Flow | 122.24M | 205.81M | 36.44M | 18.22M | (9.06M) |
| Capital Expenditures | (118.94M) | (181.35M) | (216M) | (132.24M) | (69.68M) |
| Acquisitions (Net) | (21.09M) | (83.82M) | (20.16M) | 42.78M | 213.76M |
| Purchases of Investments | (123.7M) | (355.82M) | (48.39M) | (29.39M) | (13.42M) |
| Sales of Investments | 27.25M | 205.17M | 260.36M | 35.67M | 38.87M |
| Other Investing Activities | (7.38M) | 3.03M | 8.22M | (2.78M) | 0 |
| Investing Cash Flow | (243.86M) | (412.8M) | (13.29M) | (71.19M) | 159.86M |
| Debt Repayment | 14.77M | (53.11M) | 84.6M | (152.07M) | (6.96M) |
| Common Stock Issued | 404.32M | 355K | 0 | 0 | (1.27M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.67M) | (5.39M) | (12.63M) | (9.35M) | (22.71M) |
| Financing Cash Flow | 398.43M | (58.15M) | 71.96M | (161.42M) | (30.93M) |
| Effect of Forex Changes | (66K) | (19.04M) | 644K | 9.87M | 28.46M |
| Net Change in Cash | 276.75M | (284.17M) | 95.75M | (204.52M) | 148.32M |
| Free Cash Flow | 3.29M | 24.46M | (179.56M) | (114.02M) | (78.74M) |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.